StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research note released on Thursday. The firm issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Trading Up 0.8 %
Shares of APVO stock opened at $0.41 on Thursday. The stock has a 50 day simple moving average of $0.56 and a 200 day simple moving average of $3.02. Aptevo Therapeutics has a 1 year low of $0.28 and a 1 year high of $48.40.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share for the quarter, topping the consensus estimate of ($14.10) by $4.15. On average, equities research analysts expect that Aptevo Therapeutics will post -8.86 earnings per share for the current year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Further Reading
- Five stocks we like better than Aptevo Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Call Options Volume for These 2 Stocks Spiked Together
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
